

	EMLc	ATC codes: J01DH02
<b>Indication</b>	Multi-drug resistant Mycobacterium tuberculosis	ICD11 code: ML32.00
<b>INN</b>	Meropenem	
<b>Medicine type</b>	Chemical agent	
<b>Antibiotic groups</b>	 WATCH	
<b>List type</b>	Complementary (EML) (EMLc)	
<b>Additional notes</b>	The square box applies only to the listing of meropenem on the EML.	
<b>Formulations</b>	Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection ; 1 g in vial (as trihydrate) powder for injection	
<b>EML status history</b>	First added in 2019 (TRS 1021) Changed in 2021 (TRS 1035)	
<b>Sex</b>	All	
<b>Age</b>	Also recommended for children	
<b>Therapeutic alternatives</b>	imipenem + cilastatin (ATC codes: J01DH51)	
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 	
<b>Wikipedia</b>	Meropenem 	
<b>DrugBank</b>	Meropenem 	

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended imipenem + cilastatin be specified as a therapeutic alternative under the square box listing for meropenem on the EML for this indication.

